ST. PAUL, Minn. -- New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010The research

read more>>

ROCKVILLE, MD -- EntreMed, Inc. (Nasdaq: ENMD), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AMLThe FDA accepted EntreMed’s a

read more>>

Lyon (France), Philadelphia (USA -- ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), is pleased to announce a collaborative research agreement in the field of personalized medicine focusing on ERYtech’s flagship product, GRASPA®, which consists of P

read more>>

Ninewells Hospital in Dundee has become the first national clinical centre in Scotland for treating patients with a very rare skin disorder that leaves them extremely vulnerable to sunlightOnly about ten patients in Scotland are affected by xeroderma pigmentosum - a condition first identified in t

read more>>

MIGDAL HAEMEK, Israel -- Neurodegenerative diseases such as Alzheimer's set a challenge for modern medicine, as their origins are unclear and the comprehension of the progression of symptoms often relies upon a patients' behaviorApplied Spectral Imaging (ASI) a leading provider of comprehensive im

read more>>

Cambridge, Mass. and Redwood City, Calif. -- Biogen Idec (NASDAQ: BIIB) and Facet Biotech Corporation (NASDAQ: FACT) today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged

read more>>

Bethesda, MD -- Certain patients with inflammatory bowel disease (IBD), both ulcerative colitis and Crohn's disease of the colon, have an increased risk of developing colorectal cancer compared to individuals without IBD. A number of factors contribute to the increase in risk, which necessitates an

read more>>

SALT LAKE CITY -- An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosisThis new study was published online Feb. 16, 2010, a

read more>>

BOTHELL, WA -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that CureDuchenne and the Foundation to Eradicate Duchenne (FED), each awarded grants of $250,000 to AVI BioPharma to support continued research and development of the Company’s exon skipping C

read more>>

LACHEN, Switzerland -- Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIGThe study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and

read more>>